HeartSciences Inc. (NASDAQ:HSCS) Sees Significant Decrease in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 29,118 shares, a decrease of 20.6% from the November 30th total of 36,682 shares. Approximately 0.9% of the shares of the stock are sold short. Based on an average daily volume of 69,464 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 69,464 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.9% of the shares of the stock are sold short.

HeartSciences Price Performance

Shares of HSCS traded up $0.12 during trading hours on Thursday, hitting $3.09. The stock had a trading volume of 36,961 shares, compared to its average volume of 74,765. HeartSciences has a 1-year low of $2.01 and a 1-year high of $6.47. The firm has a market capitalization of $9.83 million, a P/E ratio of -0.45 and a beta of 2.57. The firm has a 50 day simple moving average of $2.77 and a 200-day simple moving average of $3.33.

HeartSciences (NASDAQ:HSCS) last announced its quarterly earnings results on Monday, December 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.05. The firm had revenue of $2.42 million during the quarter, compared to the consensus estimate of $0.00 million. Equities analysts predict that HeartSciences will post -10.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HeartSciences stock. TFB Advisors LLC acquired a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 29,740 shares of the company’s stock, valued at approximately $105,000. TFB Advisors LLC owned about 1.12% of HeartSciences at the end of the most recent reporting period. Institutional investors and hedge funds own 17.24% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HSCS. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday. Ascendiant Capital Markets increased their price target on HeartSciences from $9.00 to $9.20 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of HeartSciences from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.20.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.